Increased rates of immunosuppressive treatment and hospitalization after checkpoint inhibitor therapy in cancer patients with autoimmune disease

Increased rates of immunosuppressive treatment and hospitalization after checkpoint inhibitor therapy in cancer patients with autoimmune disease

Background Immune checkpoint inhibitors (ICIs) are important new therapeutic options for the treatment of malignancy. Existing data on the relative safety of ICI treatment in patients with pre-existing autoimmune disease (AID) are limited.Methods In this retrospective study utilizing an oncology med...

Full description

Bibliographic Details
Main Authors:	David Andrew Bender, Samuel P Heilbroner, Tony J C Wang, Catherine A Shu, Brigham Hyde, Catherine Spina, Simon K Cheng
Format:	Article
Language:	English
Published:	BMJ Publishing Group 2020-07-01
Series:	Journal for ImmunoTherapy of Cancer
Online Access:	https://jitc.bmj.com/content/8/2/e001627.full

Similar Items

Campylobacteriosis following immunosuppression for immune checkpoint inhibitor-related toxicity
by: Heather Shaw
Published: (2020-07-01)

Dual checkpoint inhibitor induced autoimmune encephalitis
by: Elkayam Natalie, et al.
Published: (2019-01-01)

Intensified immunosuppressive therapy in patients with immune checkpoint inhibitor-induced myocarditis
by: Jennifer Cautela, et al.
Published: (2020-07-01)

PD-1 Checkpoint Inhibitor Associated Autoimmune Encephalitis
by: Stephanie Schneider, et al.
Published: (2017-05-01)

Pathophysiology of paraneoplastic and autoimmune encephalitis: genes, infections, and checkpoint inhibitors
by: Alberto Vogrig, et al.
Published: (2020-06-01)

Coexistence of Immune Checkpoint Inhibitor-Induced Autoimmune Diabetes and Pancreatitis
by: Amy L. Zhang, et al.
Published: (2021-04-01)

Liver toxicity as a limiting factor to the increasing use of immune checkpoint inhibitorsKey points
by: Eleonora De Martin, et al.
Published: (2020-12-01)

Efficacy and Toxicity of Immune -Checkpoint Inhibitors in Patients With Preexisting Autoimmune Disorders
by: Michelle Coureau, et al.
Published: (2020-05-01)

Immune Checkpoints as Therapeutic Targets in Autoimmunity
by: Christopher Paluch, et al.
Published: (2018-10-01)

The Efficacy and Safety of Immune Checkpoint Inhibitors in Patients With Cancer and Preexisting Autoimmune Disease
by: Hui Tang, et al.
Published: (2021-02-01)

Overexpression of PDE4A Acts as Checkpoint Inhibitor Against cAMP-Mediated Immunosuppression in vitro
by: Klaus G. Schmetterer, et al.
Published: (2019-07-01)

658 Toxicities of single agent and combination immune checkpoint inhibitors in patients with pre-existing autoimmune diseases
by: Jeffrey Weber, et al.
Published: (2020-11-01)

CCND1 Amplification Contributes to Immunosuppression and Is Associated With a Poor Prognosis to Immune Checkpoint Inhibitors in Solid Tumors
by: Yu Chen, et al.
Published: (2020-08-01)

Neuritin, unmasked as a checkpoint for the pathogenesis of allergy and autoimmunity
by: Michaela Lucas, et al.
Published: (2021-01-01)

Immunosuppressive therapy in autoimmune hepatitis : efficacy and toxicity
by: Dhaliwal, Harpreet K.
Published: (2018)

Early introduction of selective immunosuppressive therapy associated with favorable clinical outcomes in patients with immune checkpoint inhibitor–induced colitis
by: Hamzah Abu-Sbeih, et al.
Published: (2019-04-01)

Ocular adverse events with immune checkpoint inhibitors
by: Tony Fang, et al.
Published: (2019-09-01)

Autoimmune diseases and immunosuppressive therapy in relation to the risk of glioma
by: Tareq M. Anssar, et al.
Published: (2020-02-01)

Immune Checkpoints: Novel Therapeutic Targets to Attenuate Sepsis-Induced Immunosuppression
by: Margaret A. McBride, et al.
Published: (2021-02-01)

IMMUNE CHECKPOINT INHIBITION AND AUTOIMMUNITY: RHEUMATOLOGICAL PROBLEMS
by: E. L. Nasonov
Published: (2018-03-01)

Immune checkpoint deficiencies and autoimmune lymphoproliferative syndromes
by: Laura Gámez-Díaz, et al.
Published: (2021-08-01)

Opportunistic autoimmune disorders potentiated by immune-checkpoint inhibitors anti-CTLA-4 and anti-PD-1
by: Yi-Chi eKong, et al.
Published: (2014-05-01)

Checkpoint Inhibitors and Hepatotoxicity
by: Stephen D. H. Malnick, et al.
Published: (2021-01-01)

Susceptible loci associated with autoimmune disease as potential biomarkers for checkpoint inhibitor-induced immune-related adverse events
by: Esmée P. Hoefsmit, et al.
Published: (2019-07-01)

Association of blood biomarkers and autoimmunity with immune related adverse events in patients with cancer treated with immune checkpoint inhibitors
by: Despina Michailidou, et al.
Published: (2021-04-01)

The use of immunosuppression in autoimmune hepatitis: A current literature review
by: Angela Cropley, et al.
Published: (2017-03-01)

An evaluation of the checkpoint kinase inhibitor V158411
by: Stephens, Peter Andrew
Published: (2015)

Seronegative autoimmune autonomic ganglionopathy from dual immune checkpoint inhibition in a patient with metastatic melanoma
by: Catherine A. Gao, et al.
Published: (2019-10-01)

292 Immune checkpoint inhibitor induced overlapping cardiac and neuromuscular toxicities: Highlight of early diagnosis, early initiation of immunosuppressive therapy and multidisciplinary management
by: Robert O’Neill, et al.
Published: (2020-11-01)

Indicators of responsiveness to immune checkpoint inhibitors
by: Bradley D. Shields, et al.
Published: (2017-04-01)

Conditional immune toxicity rate in patients with metastatic renal and urothelial cancer treated with immune checkpoint inhibitors
by: Sarah Abou Alaiwi, et al.
Published: (2020-06-01)

Epigenetic Mechanisms of Resistance to Immune Checkpoint Inhibitors
by: Alexandre Perrier, et al.
Published: (2020-07-01)

Immune checkpoint inhibitor therapy in a liver transplant recipient with autoimmune disease and metastatic cutaneous squamous cell carcinoma
by: Caitlin M. Brumfiel, MS, et al.
Published: (2021-08-01)

Bone remodeling by checkpoint inhibitor
by: Hyeongjong Kim, et al.
Published: (2020-09-01)

Determinants of Resistance to Checkpoint Inhibitors
by: Linda Tran, et al.
Published: (2020-02-01)

Immune Checkpoint Inhibitors and the Heart
by: Diana Larisa Mocan-Hognogi, et al.
Published: (2021-09-01)

Checkpoint inhibitors in hematological malignancies
by: Chi Young Ok, et al.
Published: (2017-05-01)

Effectiveness of Immune Checkpoint Inhibitors in Transplant Recipients with Progressive Multifocal Leukoencephalopathy
by: Chloé Medrano, et al.
Published: (2019-11-01)

Timing of steroid initiation and response rates to immune checkpoint inhibitors in metastatic cancer
by: Richa Goel, et al.
Published: (2021-07-01)

Overview of Immune Checkpoint Inhibitors Therapy for Hepatocellular Carcinoma, and The ITA.LI.CA Cohort Derived Estimate of Amenability Rate to Immune Checkpoint Inhibitors in Clinical Practice
by: Edoardo G. Giannini, et al.
Published: (2019-10-01)